Sigma Planning Corp Esperion Therapeutics, Inc. Transaction History

Sigma Planning Corp

  • $3.32 Billion
  • Q3 2025

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 01, 2025
SELL
$1.44 - $2.34 $256,595 - $416,966
-178,191 Reduced 93.57%
12,250 $17,000
Q4 2024

Feb 03, 2025
BUY
$1.61 - $3.83 $286,902 - $682,506
178,200 Added 1455.76%
190,441 $418,000
Q3 2024

Nov 01, 2024
BUY
$1.61 - $2.73 $161 - $273
100 Added 0.82%
12,241 $20,000
Q2 2024

Aug 05, 2024
BUY
$1.84 - $3.24 $22,339 - $39,336
12,141 New
12,141 $26,000

Others Institutions Holding ESPR

# of Institutions
214
Shares Held
114M
Call Options Held
643K
Put Options Held
769K
View Full List

About Esperion Therapeutics, Inc.

ESPR Quotes by TradingView
  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $193M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Sigma Planning Corp Portfolio

Follow Sigma Planning Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

News

Stay updated on Sigma Planning Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email